{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T23:32:13Z","timestamp":1774999933709,"version":"3.50.1"},"reference-count":50,"publisher":"IMR Press","issue":"6","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Neurol."],"abstract":"<jats:p>Introduction: As Parkinson\u2019s disease progresses, symptoms develop that make it more difficult to control, either because of the presence of fluctuations despite adequate oral treatment, or because of the adverse effects caused by the continued use of levodopa, considered the gold standard. At this point in the course of the disease, there are different therapeutic alternatives that provide more continuous dopaminergic stimulation and help to improve this symptomatology: deep brain stimulation (Medtronic\u00ae: Percept\u2122 Primary Cell (PC), Percept\u2122 ReChargable (RC)), intestinal gel Levodopa\/Carbidopa (Duodopa\u00ae) o Levodopa\/Carbidopa\/Entacapona (Lecigon\u00ae), as well as subcutaneous infusion of foslevodopa\/foscarbidopa (Foslevodopa\u00ae) and continuous infusion of apomorphine (Dacepton\u00ae, Apo-Go\u00ae). Objective: Pharmacoeconomic study of the different therapies for treating advanced Parkinson\u2019s disease in Spain. Patients and Methods: Based on a Markov model, the efficacy and costs of these therapies were compared, measuring life years gained (LYG) and quality-adjusted life years (QALY). Results: Dacepton\u00ae (apomorphine) is the most cost-effective option with a cost of 20,782\u20ac\/QALY (1\u20ac = 1.0815 USD, 2025), compared to three times or more for the other therapies with Lecigon\u00ae (levodopa\/carbidopa\/entacapone) being the least cost-effective with a cost of 104,000\u20ac\/QALY. Deep brain stimulation (DBS) and Duodopa\u00ae also proved to be effective options, but more costly than Dacepton\u00ae. Conclusions: These results provide additional information on the efficiency of treatments that should inform decision-making in the management of advanced Parkinson\u2019s disease, thus enabling better resource management.<\/jats:p>","DOI":"10.31083\/rn33482","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T09:26:59Z","timestamp":1754472419000},"source":"Crossref","is-referenced-by-count":1,"title":["Cost of Quality of Life in Advanced Parkinson\u2019s Disease: Efficient Strategies for Disease Assessment"],"prefix":"10.31083","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2979-5241","authenticated-orcid":true,"given":"Nuria","family":"Garc\u00eda-Agua Soler","sequence":"first","affiliation":[{"name":"Econom\u00eda de la Salud y Uso Racional de Medicamentos, Departamento de Farmacolog\u00eda, Facultad de Medicina, 29010 M\u00e1laga, Espa\u00f1a"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA), Universidad de M\u00e1laga, 29016 M\u00e1laga, Espa\u00f1a"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Garc\u00eda Trujillo","sequence":"first","affiliation":[{"name":"Servicio de Neurolog\u00eda, Hospital Regional Universitario de M\u00e1laga, 29010 M\u00e1laga, Espa\u00f1a"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio J","family":"Garc\u00eda-Ruiz","sequence":"first","affiliation":[{"name":"Econom\u00eda de la Salud y Uso Racional de Medicamentos, Departamento de Farmacolog\u00eda, Facultad de Medicina, 29010 M\u00e1laga, Espa\u00f1a"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA), Universidad de M\u00e1laga, 29016 M\u00e1laga, Espa\u00f1a"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16242","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Mhyre TR, Boyd JT, Hamill RW, Maguire-Zeiss KA. Parkinson\u2019s disease. Sub-cellular Biochemistry. 2012; 65: 389\u2013455.","DOI":"10.1007\/978-94-007-5416-4_16"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Jankovic J, Tan EK. Parkinson\u2019s disease: etiopathogenesis and treatment. Journal of Neurology, Neurosurgery, and Psychiatry. 2020; 91: 795\u2013808.","DOI":"10.1136\/jnnp-2019-322338"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Clarke CE. Parkinson\u2019s disease. BMJ (Clinical Research Ed.). 2007; 335: 441\u2013445.","DOI":"10.1136\/bmj.39289.437454.AD"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Davie CA. A review of Parkinson\u2019s disease. British Medical Bulletin. 2008; 86: 109\u2013127.","DOI":"10.1093\/bmb\/ldn013"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Antonini A, Stoessl AJ, Kleinman LS, Skalicky AM, Marshall TS, Sail KR, et al. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson\u2019s disease: a multi-country Delphi-panel approach. Current Medical Research and Opinion. 2018; 34: 2063\u20132073.","DOI":"10.1080\/03007995.2018.1502165"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Odin P, Ray Chaudhuri K, Slevin JT, Volkmann J, Dietrichs E, Martinez-Martin P, et al. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson\u2019s disease: Consensus from an international survey and discussion program. Parkinsonism & Related Disorders. 2015; 21: 1133\u20131144.","DOI":"10.1016\/j.parkreldis.2015.07.020"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Luquin MR, Kulisevsky J, Martinez-Martin P, Mir P, Tolosa ES. Consensus on the Definition of Advanced Parkinson\u2019s Disease: A Neurologists-Based Delphi Study (CEPA Study). Parkinson\u2019s Disease. 2017; 2017: 4047392.","DOI":"10.1155\/2017\/4047392"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Das S, Matias CM, Ramesh S, Velagapudi L, Barbera JP, Katz S, et al. Capturing Initial Understanding and Impressions of Surgical Therapy for Parkinson\u2019s Disease. Frontiers in Neurology. 2021; 12: 605959.","DOI":"10.3389\/fneur.2021.605959"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Henriksen T, Dalhoff KP, Hansen HE, Brenneche AW, L\u00f8nberg US, Danielsen EH. Access and Use of Device-Aided Therapies for Parkinson\u2019s Disease in Denmark. Movement Disorders Clinical Practice. 2020; 7: 656\u2013663.","DOI":"10.1002\/mdc3.12988"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Dijk JM, Espay AJ, Katzenschlager R, de Bie RMA. The Choice Between Advanced Therapies for Parkinson\u2019s Disease Patients: Why, What, and When? Journal of Parkinson\u2019s Disease. 2020; 10: S65\u2013S73.","DOI":"10.3233\/JPD-202104"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Deuschl G, Antonini A, Costa J, \u015ami\u0142owska K, Berg D, Corvol JC, et al. European Academy of Neurology\/Movement Disorder Society - European Section guideline on the treatment of Parkinson\u2019s disease: I. Invasive therapies. European Journal of Neurology. 2022; 29: 2580\u20132595.","DOI":"10.1111\/ene.15386"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Vivancos-Matellano F, Garcia-Ruiz AJ, Garcia-Agua Soler N. Pharmacoeconomic study of the treatment of advanced Parkinson\u2019s disease. Revista De Neurologia. 2016; 63: 529\u2013536.","DOI":"10.33588\/rn.6312.2016160"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Postma MJ, Boersma C. Flexibility of Markov modeling for clinical pharmacoeconomics: illustration for cost-effectiveness in early Parkinson\u2019s disease. Expert Review of Clinical Pharmacology. 2012; 5: 1\u20134.","DOI":"10.1586\/ecp.11.69"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Aldred J, Freire-Alvarez E, Amelin AV, Antonini A, Bergmans B, Bergquist F, et al. Continuous Subcutaneous Foslevodopa\/Foscarbidopa in Parkinson\u2019s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study. Neurology and Therapy. 2023; 12: 1937\u20131958.","DOI":"10.1007\/s40120-023-00533-1"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Cox E, Wade R, Hodgson R, Fulbright H, Phung TH, Meader N, et al. Devices for remote continuous monitoring of people with Parkinson\u2019s disease: a systematic review and cost-effectiveness analysis. Health Technology Assessment. 2024; 28: 1\u2013187.","DOI":"10.3310\/YDSL3294"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Kulisevsky J, Luquin MR, Arbelo JM, Burguera JA, Carrillo F, Castro A, et al. Advanced Parkinson\u2019s disease: clinical characteristics and treatment (part 1). Neurologia (Barcelona, Spain). 2013; 28: 503\u2013521.","DOI":"10.1016\/j.nrl.2013.05.001"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Valldeoriola F, Puig-Junoy J, Puig-Peir\u00f3 R, Workgroup of the SCOPE study. Cost analysis of the treatments for patients with advanced Parkinson\u2019s disease: SCOPE study (eStudio COstes Parkinson Enfermedad). Journal of Medical Economics. 2013; 16: 191\u2013201.","DOI":"10.3111\/13696998.2012.737392"},{"key":"ref18","unstructured":"Instituto Nacional de Estad\u00edstica. \u00cdndice de Precios de Consumo. Medias anuales. \u00cdndices nacionales: general y de grupos ECOICOP. Disponible en: https:\/\/www.ine.es\/jaxiT3\/Tabla.htm?t=50934&L=0 (Accedido: 9 Octubre 2024)."},{"key":"ref19","unstructured":"Precios p\u00fablicos sanitarios. Junta de Andaluc\u00eda. 2018. Disponible en: https:\/\/www.juntadeandalucia.es\/datosabiertos\/portal\/dataset\/precios-publicos-de-servicios-sanitarios-prestados-en-el-sspa\/resource\/8b3db748-92fc-41c0-9688-44456fa8bae4 (Accedido: 4 Octubre 2024)."},{"key":"ref20","unstructured":"Precios p\u00fablicos de servicios sanitarios prestados en Sistema Sanitario P\u00fablico Andaluz. 2018. Disponible en: https:\/\/datos.gob.es\/es\/catalogo\/a01002820-precios-publicos-de-servicios-sanitarios-prestados-en-el-sspa (Accedido: 4 Octubre 2024)."},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Burkard T, L\u00f3pez-G\u00fcell K, Gorbachev A, Bellas L, J\u00f6dicke AM, Burn E, et al. Calculating daily dose in the Observational Medical Outcomes Partnership Common Data Model. Pharmacoepidemiology and Drug Safety. 2024; 33: e5809.","DOI":"10.1002\/pds.5809"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study. The Lancet. Neurology. 2014; 13: 141\u2013149.","DOI":"10.1016\/S1474-4422(13)70293-X"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VSC, Klostermann F, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s disease: final 12-month, open-label results. Movement Disorders: Official Journal of the Movement Disorder Society. 2015; 30: 500\u2013509.","DOI":"10.1002\/mds.26123"},{"key":"ref24","unstructured":"Lecigon (entacapone, carbidopa (monohydrate), levodopa). Public Assessment Report Scientific discussion. 2018. Disponible en: https:\/\/docetp.mpa.se\/LMF\/Lecigon%20intestinal%20gel%20ENG%20PAR_09001bee813fbfeb.pdf (Accedido: 7 Octubre 2024)."},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Senek M, Nielsen EI, Nyholm D. Levodopa-entacapone-carbidopa intestinal gel in Parkinson\u2019s disease: A randomized crossover study. Movement Disorders: Official Journal of the Movement Disorder Society. 2017; 32: 283\u2013286.","DOI":"10.1002\/mds.26855"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Szatm\u00e1ri S, Sz\u00e1sz JA, Orb\u00e1n-Kis K, Bar\u00f3ti B, Bataga S, Ciorba M, et al. Levodopa-Entacapone-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson\u2019s Disease: A Single Center Real-World Experience. Pharmaceutics. 2024; 16: 453.","DOI":"10.3390\/pharmaceutics16040453"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Chaudhuri KR, Kov\u00e1cs N, Pontieri FE, Aldred J, Bourgeois P, Davis TL, et al. Levodopa Carbidopa Intestinal Gel in Advanced Parkinson\u2019s Disease: DUOGLOBE Final 3-Year Results. Journal of Parkinson\u2019s Disease. 2023; 13: 769\u2013783.","DOI":"10.3233\/JPD-225105"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Antonini A, Odin P, Pahwa R, Aldred J, Alobaidi A, Jalundhwala YJ, et al. The Long-Term Impact of Levodopa\/Carbidopa Intestinal Gel on \u2018Off\u2019-time in Patients with Advanced Parkinson\u2019s Disease: A Systematic Review. Advances in Therapy. 2021; 38: 2854\u20132890.","DOI":"10.1007\/s12325-021-01747-1"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Fung VSC, Aldred J, Arroyo MP, Bergquist F, Boon AJW, Bouchard M, et al. Continuous subcutaneous foslevodopa\/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson\u2019s disease: Considerations for initiation and maintenance. Clinical Parkinsonism & Related Disorders. 2024; 10: 100239.","DOI":"10.1016\/j.prdoa.2024.100239"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Pahwa R, Pagan FL, Kremens DE, Saint-Hilaire M. Clinical Use of On-Demand Therapies for Patients with Parkinson\u2019s Disease and OFF Periods. Neurology and Therapy. 2023; 12: 1033\u20131049.","DOI":"10.1007\/s40120-023-00486-5"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Aubignat M, Tir M. Continuous Subcutaneous Foslevodopa-Foscarbidopa in Parkinson\u2019s Disease: A Mini-Review of Current Scope and Future Outlook. Movement Disorders Clinical Practice. 2024; 11: 1188\u20131194.","DOI":"10.1002\/mdc3.14161"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Poplawska-Domaszewicz K, Batzu L, Falup-Pecurariu C, Chaudhuri KR. Subcutaneous Levodopa: A New Engine for the Vintage Molecule. Neurology and Therapy. 2024; 13: 1055\u20131068.","DOI":"10.1007\/s40120-024-00635-4"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Rosebraugh M, Stodtmann S, Liu W, Facheris MF. Foslevodopa\/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum. Parkinsonism & Related Disorders. 2022; 97: 68\u201372.","DOI":"10.1016\/j.parkreldis.2022.03.012"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, et al. Apomorphine subcutaneous infusion in patients with Parkinson\u2019s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. Neurology. 2018; 17: 749\u2013759.","DOI":"10.1016\/S1474-4422(18)30239-4"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Walter E, Said M. Cost-effectiveness of apomorphine in the treatment of advance Parkinson disease in the UK and Germany: results from a multicounty decision analytic model. Value in Health. 2013; 16: A622.","DOI":"10.1016\/j.jval.2013.08.1824"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Lowin J, Bergman A, Chaudhuri KR, Findley LJ, Roeder C, Schifflers M, et al. A cost-effectiveness analysis of levodopa\/carbidopa intestinal gel compared to standard care in late stage Parkinson\u2019s disease in the UK. Journal of Medical Economics. 2011; 14: 584\u2013593.","DOI":"10.3111\/13696998.2011.598201"},{"key":"ref37","unstructured":"Pollak P, Champay AS, Gaio JM, Hommel M, Benabid AL, Perret J. Subcutaneous administration of apomorphine in motor fluctuations in Parkinson\u2019s disease. Revue Neurologique. 1990; 146: 116\u2013122."},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Sch\u00e4fer H, B\u00f6tzel K, et al. A randomized trial of deep-brain stimulation for Parkinson\u2019s disease. The New England Journal of Medicine. 2006; 355: 896\u2013908.","DOI":"10.1056\/NEJMoa060281"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Tomaszewski KJ, Holloway RG. Deep brain stimulation in the treatment of Parkinson\u2019s disease: a cost-effectiveness analysis. Neurology. 2001; 57: 663\u2013671.","DOI":"10.1212\/wnl.57.4.663"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Garc\u00eda Ruiz PJ, Sesar Ignacio A, Ares Pensado B, Castro Garc\u00eda A, Alonso Frech F, Alvarez L\u00f3pez M, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson\u2019s disease with motor fluctuations: a multicenter study. Movement Disorders: Official Journal of the Movement Disorder Society. 2008; 23: 1130\u20131136.","DOI":"10.1002\/mds.22063"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Palmer CS, Schmier JK, Snyder E, Scott B. Patient preferences and utilities for \u2018off-time\u2019 outcomes in the treatment of Parkinson\u2019s disease. Quality of Life Research: an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation. 2000; 9: 819\u2013827.","DOI":"10.1023\/a:1008903126315"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Garc\u00eda-Ramos R, L\u00f3pez Vald\u00e9s E, Ballesteros L, Jes\u00fas S, Mir P. The social impact of Parkinson\u2019s disease in Spain: Report by the Spanish Foundation for the Brain. Neurologia (Barcelona, Spain). 2016; 31: 401\u2013413.","DOI":"10.1016\/j.nrl.2013.04.008"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Martinez-Mart\u00edn P, Rodriguez-Blazquez C, Paz S, Forjaz MJ, Frades-Payo B, Cubo E, et al. Parkinson Symptoms and Health Related Quality of Life as Predictors of Costs: A Longitudinal Observational Study with Linear Mixed Model Analysis. PloS One. 2015; 10: e0145310.","DOI":"10.1371\/journal.pone.0145310"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Fernandez HH, Odin P, Standaert DG, Henriksen T, Jimenez-Shahed J, Metz S, et al. Healthcare resource utilization and device-aided therapy discussions with eligible patients across the Parkinson\u2019s disease continuum: Revelations from the MANAGE-PD validation cohort. Parkinsonism & Related Disorders. 2023; 116: 105514.","DOI":"10.1016\/j.parkreldis.2023.105514"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Gomez-Inhiesto E, Acaiturri-Ayesta MT, Ustarroz-Aguirre I, Camahuali D, Urtaran-Laresgoiti M, Basabe-Aldecoa M, et al. Direct Cost of Parkinson\u2019s Disease: A Real-World Data Study of Second-Line Therapies. Parkinson\u2019s Disease. 2020; 2020: 9106026.","DOI":"10.1155\/2020\/9106026"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Zhao YJ, Tan LCS, Au WL, Heng DMK, Soh IAL, Li SC, et al. Estimating the lifetime economic burden of Parkinson\u2019s disease in Singapore. European Journal of Neurology. 2013; 20: 368\u2013374.","DOI":"10.1111\/j.1468-1331.2012.03868.x"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"von Campenhausen S, Winter Y, Rodrigues e Silva A, Sampaio C, Ruzicka E, Barone P, et al. Costs of illness and care in Parkinson\u2019s disease: an evaluation in six countries. European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology. 2011; 21: 180\u2013191.","DOI":"10.1016\/j.euroneuro.2010.08.002"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Vallejo-Torres L, Garc\u00eda-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. Health Economics. 2018; 27: 746\u2013761.","DOI":"10.1002\/hec.3633"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Sacrist\u00e1n JA, Oliva J, Campillo-Artero C, Puig-Junoy J, Pinto-Prades JL, Dilla T, et al. What is an efficient health intervention in Spain in 2020? Gaceta Sanitaria. 2020; 34: 189\u2013193.","DOI":"10.1016\/j.gaceta.2019.06.007"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Kalabina S, Belsey J, Pivonka D, Mohamed B, Thomas C, Paterson B. Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson\u2019s disease in patients in Scotland and Wales. Journal of Medical Economics. 2019; 22: 215\u2013225.","DOI":"10.1080\/13696998.2018.1553179"}],"container-title":["Revista de Neurolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RN\/80\/6\/10.31083\/RN33482","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T09:27:17Z","timestamp":1754472437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RN\/80\/6\/10.31083\/RN33482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"alternative-id":["S0210-0010(25)00049-0"],"URL":"https:\/\/doi.org\/10.31083\/rn33482","relation":{},"ISSN":["0210-0010","1576-6578"],"issn-type":[{"value":"0210-0010","type":"print"},{"value":"1576-6578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"article-number":"33482"}}